Interwencjonizm państwowy a dostępność opieki zdrowotnej

• Autorzy: Katarzyna Nowicka

Warianty tytułu

State Interventionism and Accessibility of Health Care

• Języki publikacji: PL

Abstrakty

EN

The efficiency of cooperation between the members in a medicine supply chain is expressed by the level of accessibility of medicines in particular countries. The metrix system of dependency of the subjects having impact on fulfilling customer's needs points to the quality of the tools of trading policy selected by the state as a determiner of the ratio of well-being of its citizens. Also, due to the decreasing importance of charging measures, key significance for protecting the domestic market is attributed to not harmonized administrative and legal regulations. While it is relatively simple to draw and introduce a directive, enforcing its implementation on the administrative level requires developing equally effective executory procedures. Otherwise, fulfilling patient's needs with either foreign or domestric medicine can be impeded substantially. The quality of social health, and therefore the productiveness of a society, is not related merely to the range of economic develoment of given country, but also to the effectiveness of the administrative and legal regulations in force. A specific spiral of interdependencies is created, where the major role seems to be attributed to the skill of selecting the instruments of trading policy ensuring high level of access to state-of-the-art pharmacotherapies without a loss for the development of domestic industry, but with a provision of certain stimuli for it.(original abstract)

Słowa kluczowe

PL

Interwencjonizm państwa; Opieka zdrowotna; Leki

EN

Government intervention; Health care; Medications

• Czasopismo: Problemy Zarządzania
• Rocznik: 2006
• Tom: 4
• Numer: nr 2(12) Zarządzanie i marketing
• Strony: 61--79

Twórcy

autor

Katarzyna Nowicka

• SGH Warsaw School of Economics

Bibliografia

• Alliance for Retired Americans Organization. 2003. Prescription Drugs, Washington: Alliance for Retired Americans, www.retiredamericans.org.
• Artykuł 66.1 i 70.9 porozumienia WTO TRIPs.
• Australian Industry Commission. 1996. The Pharmaceutical Industry, Melbourne: Australian Govemment Publishing Service.
• Baker, B. 2004. Processes and Issues for Improving Access to Medicines. Willingness and Ability to Utilize TRIPS Flexibilities in Non-Producing Countries, London: DFID Health System Resource Centre.
• Bale, H. 2001. Consumption and Trade in Off-Patented Medicines, Working Paper, nr WG 4:3, Geneva: WHO, Commission on Macroeconomic and Health.
• Bennett, S., Quick, J. i G. Velasques. 1997. Public-Private Roles in the Pharmaceutical Sector: Implications for equitable access and rational drug use, Geneva: WHO.
• Cambridge Pharma Consultancy. 2002. Delays To Market Access In Europe, Cambridge: Cambridge Pharma Consultancy.
• Cao, A.O. 1980. Non-tariff Barriers to U. S. Manufactured Exports. Columbia Journal of World Business, Summer 1980.
• Conlin, L. 2001. Using Trade Promotion Authority to Reduce Non-Tariff Barriers, Export America, September 2001.
• Correra, C. 2002. Implementations of the Doha Declaration on the TRIPs Agreement and Public Health, Geneva: WHO.
• Dukes, M., Haaijer-Ruskamp, F., de Joncheere, C. i A. Rierveld. 2003. Drugs and Money: Prices, Affordability and Cost Containment, Geneva: WHO.
• EFPIA. 2005. The Pharmaceutical Industry in Figures. Key Data, 2005 Update, Brussels: EFPIA.
• Ernst & Young. 2004. Time for Checkup: Trade Issues In Heath Sciences, Davos: World EconomicForum 2004.
• European Commission. 2003. Working document on developing countries duties and taxes onessential medicines used in the treatment of major communicable diseases, Brussels: EuropeanCommission.
• Kanavos, P. 2002. EU pharmaceutical Policy. The challenges and opportunities of enlargement w:Eurohealth Vol. 8 no 4 Autum 2002.
• Kondrat, M. 2003. Import równoległy leków. Gazeta Prawna -Biznes i Prawo nr 57 (913), 21-23marca.
• Krasovec, K. i C. Connor. 1998. Survey on Tax Treatment of Public Health Commodities. TechnicalReport no. 17, Partnership for Health Reform Project, Bethesda : Abt Associates Inc.
• Levison, L. 2003. Policy and programming options for reducing the procurement costs of essentialmedicines in developing countries, Boston: Boston University School of Public Health.
• Mossialos, E., Mrazek, M. i T. Walley. 2004. Regulating pharmaceuticals in Europe: striving forefficiency, equity and quality, Berkshire: Open University Press.
• Ratanawijitrasin, S. i E. Wondemagegnehu. 2002. Effective Drug Regulation: a Multicountry Study,Geneva: WHO.
• Schiavo-Campo, S. 1999. Simplification of Customs Procedures: reducing transaction costs forefficiency, integrity and trade facilitation, Asian Development Bank.
• Shaw, R. i A. Elmendorf. 1994. Better health in Africa, Washington: The International Bank forReconstruction and Development/ The World Bank.
• WHO. 1946. Constitution of the World Health Organization, New York, Geneva.
• WHO. 1998. Selected Topics in Health Reform and Drug Financing, WHO Action Program on EssentialDrugs, Geneva: WHO.
• WHO. 2000a. The World Heath Report 2000. Health Systems: Improving Performance, Geneva: WHO.
• WHO. 2000b. WHO Medicines Strategy 2000-2003: Framework for Action In Essentials Drugs andMedicines Policy, Geneva: WHO.
• WHO. 2005. Pharmaceutical Tariffs: What is their effect on prices, protection of local industry andrevenue generation? Geneva: WHO Secretariat for Commission on Intellectual Property Rights,Innovation and Public Health.
• WHO-WTO. 2001. More equitable pricing for essential drugs: what do we mean and what are theissues? Geneva: WHO Secretariat.
• Woodward, D. 2001. Trade Barriers and Prices of Essential Health Sector Inputs, New Delhi: IndianCouncil for Research on International Economics Relations.
• World Bank. 1994. Towards Better Health in Sub Saharan Africa. Findings, nr 25.
• ---